BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24830360)

  • 1. The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.
    Wang L; Day J; Roe CM; Brier MR; Thomas JB; Benzinger TL; Morris JC; Ances BM
    Alzheimer Dis Assoc Disord; 2014; 28(2):122-7. PubMed ID: 24830360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
    Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
    Scacchi R; Gambina G; Broggio E; Corbo RM
    Int J Geriatr Psychiatry; 2014 Jun; 29(6):610-5. PubMed ID: 24150894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
    Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
    J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH; Kim SY; Na HR; Kim BK; Yang DW; Kwon JC; Park MY
    Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E ε4 modulates functional brain connectome in Alzheimer's disease.
    Wang J; Wang X; He Y; Yu X; Wang H; He Y
    Hum Brain Mapp; 2015 May; 36(5):1828-46. PubMed ID: 25619771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report.
    Zaidel L; Allen G; Cullum CM; Briggs RW; Hynan LS; Weiner MF; McColl R; Gopinath KS; McDonald E; Rubin CD
    J Alzheimers Dis; 2012; 31 Suppl 3(0 3):S221-6. PubMed ID: 22886013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
    Blesa R; Aguilar M; Casanova JP; Boada M; Martínez S; Alom J; de la Hoz CH; Sancho J; Fernández O; Gil-Neciga E; Massó JF
    Alzheimer Dis Assoc Disord; 2006; 20(4):248-54. PubMed ID: 17132969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E ε4 Modulates Cognitive Profiles, Hippocampal Volume, and Resting-State Functional Connectivity in Alzheimer's Disease.
    Wang X; Wang J; He Y; Li H; Yuan H; Evans A; Yu X; He Y; Wang H
    J Alzheimers Dis; 2015; 45(3):781-95. PubMed ID: 25624419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
    Wattmo C; Wallin AK; Minthon L
    BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
    Venneri A; Lane R
    Neuroreport; 2009 Feb; 20(3):285-8. PubMed ID: 19444953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.